Sasan Roayaie
Overview
Explore the profile of Sasan Roayaie including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
101
Citations
10236
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Llovet J, Kelley R, Villanueva A, Singal A, Pikarsky E, Roayaie S, et al.
Nat Rev Dis Primers
. 2024 Feb;
10(1):10.
PMID: 38346997
No abstract available.
2.
Raff J, Cook B, Jafri F, Boxer N, Maldonado J, Hopkins U, et al.
Pancreas
. 2023 Apr;
51(10):1345-1351.
PMID: 37099777
Objectives: Guidelines for testing individuals at risk (IAR) for developing pancreatic duct adenocarcinoma (PC) are being advanced from university hospital populations. We implemented a screen-in criteria and protocol for IAR...
3.
Torrens L, Puigvehi M, Torres-Martin M, Wang H, Maeda M, Haber P, et al.
Clin Cancer Res
. 2022 Aug;
28(20):4509-4520.
PMID: 35998012
Purpose: Mongolia has the world's highest incidence of hepatocellular carcinoma (HCC), with ∼100 cases/100,000 inhabitants, although the reasons for this have not been thoroughly delineated. Experimental Design: We performed a...
4.
Montironi C, Castet F, Haber P, Pinyol R, Torres-Martin M, Torrens L, et al.
Gut
. 2022 Feb;
72(1):129-140.
PMID: 35197323
Objective: We previously reported a characterisation of the hepatocellular carcinoma (HCC) immune contexture and described an immune-specific class. We now aim to further delineate the immunogenomic classification of HCC to...
5.
Llovet J, Kelley R, Villanueva A, Singal A, Pikarsky E, Roayaie S, et al.
Nat Rev Dis Primers
. 2021 Jan;
7(1):6.
PMID: 33479224
Liver cancer remains a global health challenge, with an estimated incidence of >1 million cases by 2025. Hepatocellular carcinoma (HCC) is the most common form of liver cancer and accounts...
6.
Montal R, Sia D, Montironi C, Leow W, Esteban-Fabro R, Pinyol R, et al.
J Hepatol
. 2020 Mar;
73(2):315-327.
PMID: 32173382
Background & Aims: Cholangiocarcinoma (CCA), a deadly malignancy of the bile ducts, can be classified based on its anatomical location into either intrahepatic (iCCA) or extrahepatic (eCCA), each with different...
7.
Mazzaferro V, Gorgen A, Roayaie S, Droz Dit Busset M, Sapisochin G
J Hepatol
. 2020 Jan;
72(2):364-377.
PMID: 31954498
The incidence of intrahepatic cholangiocarcinoma (iCCA) is increasing worldwide. Although several advances have been made in the past decades to better understand this complex malignancy and to develop new treatment...
8.
Chen W, Warner R, Harpaz N, Zhu H, Roayaie S, Kim M
Pancreas
. 2018 Dec;
48(1):131-134.
PMID: 30531243
Our group observed the first case of synchronous gastric neuroendocrine tumor (NET) and duodenal gastrinoma with autoimmune chronic atrophic gastritis (CAG), in the absence of Helicobacter pylori infection. Demographic, clinical,...
9.
Chan A, Zhong J, Berhane S, Toyoda H, Cucchetti A, Shi K, et al.
J Hepatol
. 2018 Sep;
69(6):1284-1293.
PMID: 30236834
Background & Aims: Resection is the most widely used potentially curative treatment for patients with early hepatocellular carcinoma (HCC). However, recurrence within 2 years occurs in 30-50% of patients, being...
10.
Pinyol R, Montal R, Bassaganyas L, Sia D, Takayama T, Chau G, et al.
Gut
. 2018 Aug;
68(6):1065-1075.
PMID: 30108162
Objective: Sorafenib is the standard systemic therapy for advanced hepatocellular carcinoma (HCC). Survival benefits of resection/local ablation for early HCC are compromised by 70% 5-year recurrence rates. The phase 3...